Determinants of uncontrolled hypertension in an African-American population

Ethnicity and Disease

Volumn 12, Issue 4, 2002, Pages

  Jackson, James H ^a   Bramley, Thomas J ^a   Chiang, Tina H ^a   Jhaveri, Vishu ^b   Frech, Feride ^c  

^a NAVIGANT CONSULTING INC   (United States)

^b Keystone Health Plan Central   (United States)

^c Novatri's Pharmaceuticals Corp   (United States)

Author keywords

ACE inhibitors; African American; Diabetes; Hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; ETHNIC GROUP; FAMILY HISTORY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEGRO; POPULATION RESEARCH; RISK ASSESSMENT; RISK FACTOR; SAMPLING; STROKE; TOBACCO;

ADULT; AFRICAN AMERICANS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; FEMALE; HUMANS; HYPERTENSION; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES;

EID: 0036763393     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2001:1-35.
2. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2002;25[suppl 1]:S71-S73.
3. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157:2413-2446.
4. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;5(277):739-745.
5. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990; 335:827-838.
6. Neal B, MacMahon S. An overview of 37 randomized trials of blood pressure lowering agents among 270,000 individuals. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Clin Exp Hypertens. 1999;21:517-529.
7. Personal communication, James H. Jackson IV, PharmD, Applied Health Outcomes, Tampa, Florida, May 2002.
8. US Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health. 2nd ed. Washington, DC: US Government Printing Office; November 2000.
9. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. Aug 16, 2001; 345(7):479-486.
10. He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. Seven-year incidence of hypertension in a cohort of middle-aged African Americans and Whites. Hypertension. 1998;31(5):1130-1135.
11. Cushman WC, Reda DJ, Perry HM, et al, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch Intern Med. 2000;160:825-831.
12. Flack JM, Saunders E, Gradman A, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther. 2001; 23:1193-1208.
13. Weir MR, Gray JM, Paster R, Saunders E, for the Trandolapril Multicenter Study Group. Differing mechanisms of action of angiotensin-converting enzyme inhibition in Black and White hypertensive patients. Hypertension. 1995;26:124-130.
14. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
15. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342: 145-153.
16. Sewers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053-1059.
17. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719-2728.
18. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002;162:413-420.
19. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
20. Staessen JA, Fagard R, Thijs L, et al, for the Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
21. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317: 703-713.